No Picture
News

Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain

– Complete Response Letter Requests Additional Non-Clinical Information — No Clinical Safety or Efficacy Issues and No Chemistry, Manufacturing and Controls (CMC) Issues Identified — Conference Call and Webcast Today at 9:00 a.m. ET –

SAN DIEGO, Ju… […]

No Picture
News

Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML

– Phase 1b: 7 (33%) of evaluable patients achieved an objective response, with a complete response (CR/CRi) in 5 (31%) patients treated at the four highest onvansertib dose levels- 3 (60%) of the 5 patients remain on treatment with durable response d… […]

No Picture
News

Dermata Announces Positive Results from its Phase 2b Clinical Trial of Once Weekly Topical Application of DMT310 for the Treatment of Moderate to Severe Acne Vulgaris

– DMT310 achieved IGA success (2-point change & 0 or 1) in 44.4% of patients versus 17.8% of placebo patients (p=0.0003)- DMT310 saw a -15.6 mean change from baseline in inflammatory lesion count versus a -10.8 mean change from baseline for placebo (p=… […]

No Picture
News

Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation

— Initiation of Expanded Access Program follows FDA granting Fast Track Designation of onvansertib for second-line treatment of patients with KRAS-mutation mCRC– Expanded Access Program provides pathway for patients to gain access to treatment with o… […]

No Picture
News

Neurocrine Biosciences Reports Positive Phase II Data for Crinecerfont in Adults with Congenital Adrenal Hyperplasia at ENDO Online 2020

– Crinecerfont Demonstrates Meaningful Reductions in Key Disease Biomarkers After 14 Days of Treatment- Initiation of Global Registrational Study of Crinecerfont in Adults Planned for Second Half 2020

SAN DIEGO, June 8, 2020 /PRNewswire/ — Neur… […]

No Picture
News

Heron Therapeutics Announces Publication of Results from Study 209, a Phase 2b Study of HTX-011 in Patients Undergoing Total Knee Arthroplasty

SAN DIEGO, June 4, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet … […]

No Picture
News

Global Coalition for Adaptive Research (GCAR) Selects DelMar Pharmaceuticals’ VAL-083 to Participate in the GBM AGILE Pivotal Study, an Adaptive Clinical Trial Platform in Glioblastoma Multiforme

GBM AGILE is the world’s first global adaptive clinical trial platform for glioblastoma with regulatory support as a registrational studyVAL-083 selected as the next investigational therapy to be evaluated across multiple international trial sitesReduc… […]

No Picture
News

Qualigen Therapeutics Releases FastPack® SARS-CoV-2 Antibody Diagnostic Test to University of Louisville to Conduct Validation Studies

CARLSBAD, Calif., June 2, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (Qualigen or the Company) announced today that the Company has released a pre-launch supply of its proposed FastPack® SARS-CoV-2 IgG Immunoassay diagnostic tes… […]

No Picture
News

DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2020 American Association for Cancer Research Virtual Annual Meeting II

SAN DIEGO, June 1, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that two posters updating r… […]